 |
29 Products |  |
56 Diseases | | 29 Products |
|
154 Trials |  |
7457 News |  |
| «12...8687888990919293949596...9798» |
- ||||||| Goofice (elobixibat) / Eisai, Mochida, Ipsen
Trial completion: Safety and Tolerability Extension Trial for Patients With Chronic Idiopathic Constipation (clinicaltrials.gov) - May 21, 2015
P3, N=411, Completed, Sponsor: Ferring Pharmaceuticals
Active, not recruiting --> Completed
- || Zomacton (somatropin) / Ferring
Trial completion, Enrollment change: A Follow-up Study to Examine the Presence of Anti-human Growth Hormone Antibodies Following a Study (FE 999905 CS07) of Zomacton in Children With Growth Hormone Deficiency (clinicaltrials.gov) - May 5, 2015
P3, N=23, Completed, Sponsor: Ferring Pharmaceuticals
Active, not recruiting --> Completed Enrolling by invitation --> Completed | N=46 --> 23
- Cimzia (certolizumab pegol) / Astellas, UCB
Trial primary completion date: CRIB: A Multicener, Postmarketing Study Evaluating the Transfer of Cimzia From the Mother to the Infant Via the Placenta (clinicaltrials.gov) - May 1, 2015
P1, N=20, Recruiting, Sponsor: UCB BIOSCIENCES, Inc.
Enrolling by invitation --> Completed | N=46 --> 23 Trial primary completion date: Jul 2015 --> Oct 2015
- ||||| Bimzelx (bimekizumab) / UCB, Cimzia (certolizumab pegol) / Astellas, UCB
Clinical: Multiple Dose Study of UCB4940 as add-on to Certolizumab Pegol in Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Apr 30, 2015
P2, N=102, Recruiting, Sponsor: UCB Celltech
- ||||| Rekovelle (follitropin delta) / Ferring
Enrollment closed: ESTHER-2: Evidence-based Stimulation Trial With Human rFSH in Europe and Rest of World 2 (clinicaltrials.gov) - Apr 27, 2015
P3, N=400, Active, not recruiting, Sponsor: Ferring Pharmaceuticals
Trial primary completion date: Jul 2015 --> Oct 2015 Enrolling by invitation --> Active, not recruiting
- | cyclophosphamide / Generic mfg.
Trial completion, Trial primary completion date, IO biomarker: A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer (clinicaltrials.gov) - Apr 21, 2015
P1/2, N=29, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Enrolling by invitation --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Oct 2015 --> Apr 2015
- |||||||||| Hernicore (condoliase) / Seikagaku, Ferring
New P3 trial: A Study of SI-6603 in Patients With Lumbar Disc Herniation (clinicaltrials.gov) - Apr 20, 2015
P3, N=1000, Recruiting, Sponsor: Seikagaku Corporation
- Firmagon (degarelix) / Astellas, Ferring
Trial primary completion date, PARP Biomarker: Androgen Deprivation Therapy Prior to Prostatectomy for Patients with Intermediate and High Risk Prostate Cancer (clinicaltrials.gov) - Apr 19, 2015
P=N/A, N=45, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center.
Active, not recruiting --> Completed | Trial primary completion date: Oct 2015 --> Apr 2015 Trial primary completion date: Feb 2015 --> Feb 2016
- Menopur (menotropin) / Ferring
New trial: Mono-menotropins Versus rFSH Protocol on Embryo Quality (clinicaltrials.gov) - Apr 16, 2015
P=N/A, N=100, Recruiting, Sponsor: Main Line Fertility Center
- ||| Cervidil (dinoprostone) / Ferring
New trial: Concurrent Oxytocin With Membrane Sweeping Versus Dinoprostone Pessary in Labor Induction of Nulliparas at Term (clinicaltrials.gov) - Apr 14, 2015
P=N/A, N=140, Recruiting, Sponsor: Seoul National University Hospital
- Cimzia (certolizumab pegol) / Astellas, UCB
Trial primary completion date: Cimzia Versus Mesalamine for Crohn's Recurrence (clinicaltrials.gov) - Apr 14, 2015
P4, N=24, Recruiting, Sponsor: Milton S. Hershey Medical Center
Trial primary completion date: Feb 2015 --> Feb 2016 Trial primary completion date: Dec 2014 --> Dec 2016
- |||| Bravelle (urofollitropin) / Ferring
Trial primary completion date, Head-to-Head: Evaluation of Efficacy and Safety of Highly Purified Urofollitropin for Ovulation Induction in Chinese Females (clinicaltrials.gov) - Apr 14, 2015
P3, N=212, Recruiting, Sponsor: Ferring Pharmaceuticals
Trial primary completion date: Dec 2014 --> Dec 2016 Trial primary completion date: Jul 2015 --> Oct 2015
- Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion, Enrollment change: Certolizumab and Lower Extremity Lymph Flow in Rheumatoid Arthritis (RA) (clinicaltrials.gov) - Apr 8, 2015
P4, N=5, Completed, Sponsor: University of Rochester
Trial primary completion date: Jul 2015 --> Oct 2015 Recruiting --> Completed | N=10 --> 5
- |||||| Pentasa enema (mesalazine rectal enema) / Ferring, Pentasa (mesalamine) / Ferring, Takeda
Enrollment open, Head-to-Head: An Efficacy and Safety Study of PENTASA in Chinese Patients With Left-sided Active Ulcerative Colitis Followed by a 24-Week Open-Label Extension Phase (clinicaltrials.gov) - Mar 31, 2015
P3, N=249, Recruiting, Sponsor: Ferring Pharmaceuticals
Recruiting --> Completed | N=10 --> 5 Not yet recruiting --> Recruiting
- ||||| Testavan (transdermal testosterone gel 2%) / Ferring
Enrollment closed: A Clinical Trial to Evaluate the Efficacy and Safety of Testosterone Gel in Adult Hypogonadal Males (clinicaltrials.gov) - Mar 31, 2015
P3, N=159, Active, not recruiting, Sponsor: Ferring Pharmaceuticals
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Cetrotide (cetrorelix) / EMD Serono, Lutrelef (gonadorelin acetate) / Ferring
Trial completion: Reproductive Hormonal Alterations in Obesity (clinicaltrials.gov) - Mar 28, 2015
P=N/A, N=62, Completed, Sponsor: University of Colorado, Denver
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Elonva (corifollitropin alfa) / Organon
Enrollment open, Trial primary completion date, HEOR, Cost effectiveness: Use of Corifolitropin Alfa in Oocyte Donors (clinicaltrials.gov) - Mar 26, 2015
P4, N=300, Recruiting, Sponsor: IVI Madrid
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2014 --> Jun 2015
- |||| Firmagon (degarelix) / Astellas, Ferring
Enrollment open, Monotherapy: High-Dose Brachytherapy in Treating Patients With Prostate Cancer (clinicaltrials.gov) - Mar 24, 2015
P1/2, N=163, Recruiting, Sponsor: Stanford University
Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2014 --> Jun 2015 Not yet recruiting --> Recruiting
- Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment open: A Study of Certolizumab Pegol to Evaluate Pharmacokinetics and Safety in Adult Healthy Chinese Subjects (clinicaltrials.gov) - Mar 21, 2015
P1, N=36, Recruiting, Sponsor: UCB Pharma SA
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Goofice (elobixibat) / Eisai, Mochida, Ipsen
New P2 trial: Elobixibat Colonic Motor Function Study (clinicaltrials.gov) - Mar 20, 2015
P2, N=36, Not yet recruiting, Sponsor: Ferring Pharmaceuticals
- Cervidil (dinoprostone) / Ferring
Trial primary completion date: CYTOPRO: Comparison Between 25 (clinicaltrials.gov) - Mar 11, 2015
P2, N=1200, Recruiting, Sponsor: University Hospital, Toulouse
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2014 --> May 2015
- | cyclophosphamide / Generic mfg.
Enrollment closed, IO biomarker: A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer (clinicaltrials.gov) - Mar 11, 2015
P1/2, N=32, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Trial primary completion date: Sep 2014 --> May 2015 Recruiting --> Active, not recruiting
- ||||||| Euflexxa (hyaluronic acid) / Ferring
Trial completion, Trial primary completion date, Head-to-Head: Non-Inferiority Study Comparing 3 Weekly Injections of SUPARTZ (clinicaltrials.gov) - Mar 11, 2015
P3, N=421, Completed, Sponsor: Bioventus LLC
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Jul 2015 --> Feb 2015
- |||| Bravelle (urofollitropin) / Ferring
Trial primary completion date, Head-to-Head: Evaluation of Efficacy and Safety of Highly Purified Urofollitropin for Ovulation Induction in Chinese Females (clinicaltrials.gov) - Mar 9, 2015
P3, N=180, Recruiting, Sponsor: Ferring Pharmaceuticals
Active, not recruiting --> Completed | Trial primary completion date: Jul 2015 --> Feb 2015 Trial primary completion date: Feb 2015 --> Jul 2015
- || Euflexxa (hyaluronic acid) / Ferring
Trial primary completion date: Effectiveness Trial for Evaluating IAHA for PFPS (clinicaltrials.gov) - Feb 26, 2015
P4, N=68, Recruiting, Sponsor: New York University School of Medicine
Trial primary completion date: Feb 2015 --> Jul 2015 Trial primary completion date: May 2015 --> May 2016
- |||||| Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment open: CIMPACT: Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO) (clinicaltrials.gov) - Feb 25, 2015
P3, N=540, Recruiting, Sponsor: UCB Biopharma S.P.R.L.
Trial primary completion date: May 2015 --> May 2016 Not yet recruiting --> Recruiting
- |||||||||| Pentasa enema (mesalazine rectal enema) / Ferring, Pentasa (mesalamine) / Ferring, Takeda
New P3 trial, Head-to-Head: An Efficacy and Safety Study of PENTASA in Chinese Patients With Left-sided Active Ulcerative Colitis Followed by a 24-Week Open-Label Extension Phase (clinicaltrials.gov) - Feb 23, 2015
P3, N=249, Not yet recruiting, Sponsor: Ferring Pharmaceuticals
- | Cimzia (certolizumab pegol) / Astellas, UCB
New P1 trial: A Study of Certolizumab Pegol to Evaluate Pharmacokinetics and Safety in Adult Healthy Chinese Subjects (clinicaltrials.gov) - Feb 19, 2015
P1, N=36, Not yet recruiting, Sponsor: UCB Pharma SA
- Climara (estradiol) / Bausch Health, Bayer, Lutrelef (gonadorelin acetate) / Ferring
Trial completion, Enrollment change, Trial primary completion date: Estrogen Sensitivity and Ovulatory Dysfunction in Obesity (clinicaltrials.gov) - Feb 19, 2015
P=N/A, N=30, Completed, Sponsor: University of Colorado, Denver
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | N=20 --> 30 | Trial primary completion date: Oct 2015 --> Jan 2013
- || Cervidil (dinoprostone) / Ferring
Trial primary completion date: Safety and Efficacy of Dinoprostone (Propess) in the Women With Premature Rupture of Membrane or Gestational Age <38 (clinicaltrials.gov) - Feb 12, 2015
P2, N=194, Recruiting, Sponsor: Seoul National University Hospital
Active, not recruiting --> Completed | N=20 --> 30 | Trial primary completion date: Oct 2015 --> Jan 2013 Trial primary completion date: Dec 2014 --> Oct 2015
- ||||| Rekovelle (follitropin delta) / Ferring
Enrollment closed: ESTHER-1: Evidence-based Stimulation Trial With Human rFSH in Europe and Rest of World 1 (clinicaltrials.gov) - Feb 11, 2015
P3, N=1150, Active, not recruiting, Sponsor: Ferring Pharmaceuticals
Trial primary completion date: Dec 2014 --> Oct 2015 Recruiting --> Active, not recruiting
- Firmagon (degarelix) / Astellas, Ferring
Trial primary completion date: Degarelix in the Treatment of Endometriosis Recurrence (clinicaltrials.gov) - Feb 5, 2015
P3, N=100, Recruiting, Sponsor: Centre for Endocrinology and Reproductive Medicine, Italy
Recruiting --> Active, not recruiting Trial primary completion date: Aug 2014 --> Jul 2015
- Firmagon (degarelix) / Astellas, Ferring
Trial primary completion date: Use of Degarelix in Controlled Ovarian Hyperstimulation (COH) Protocol for Women With PoliCystic Ovarian Syndrome (PCOS) (clinicaltrials.gov) - Feb 5, 2015
P3, N=80, Recruiting, Sponsor: Centre for Endocrinology and Reproductive Medicine, Italy
Trial primary completion date: Aug 2014 --> Jul 2015 Trial primary completion date: Oct 2014 --> Jun 2015
- |||| Menopur (menotropin) / Ferring
Enrollment open: HRT Versus MOS for Endometrial Preparation Prior to FET in Non PCOS Patients (clinicaltrials.gov) - Feb 4, 2015
P4, N=150, Recruiting, Sponsor: Mansoura University
Trial primary completion date: Oct 2014 --> Jun 2015 Not yet recruiting --> Recruiting
- |||| Cimzia (certolizumab pegol) / Astellas, UCB
Trial primary completion date: PreCePRA: Prediction of Response to Certolizumab Pegol Treatment by Functional MRI of the Brain (clinicaltrials.gov) - Feb 3, 2015
P3, N=156, Recruiting, Sponsor: University of Erlangen-N
Not yet recruiting --> Recruiting Trial primary completion date: Aug 2015 --> Aug 2016
- ||| Cimzia (certolizumab pegol) / Astellas, UCB
Clinical: CIMAX: A Study to Assess the Effectiveness of Certolizumab Pegol in Patients With Axial Spondyloarthritis in Daily Life (clinicaltrials.gov) - Feb 3, 2015
P=N/A, N=678, Recruiting, Sponsor: UCB Biopharma S.P.R.L.
- ||||| Orencia (abatacept) / BMS, Actemra IV (tocilizumab) / Roche, JW Pharma
New P4 trial: MAZERATI: Mechanistic Studies of B- and T-Cell Function in RA Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept (clinicaltrials.gov) - Feb 3, 2015
P4, N=90, Not yet recruiting, Sponsor: University of Pittsburgh
- Cimzia (certolizumab pegol) / Astellas, UCB
Phase classification: CRADLE: A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia (clinicaltrials.gov) - Feb 2, 2015
P1, N=16, Recruiting, Sponsor: UCB BIOSCIENCES, Inc.
Trial primary completion date: Aug 2015 --> Aug 2016 Phase classification: P1b --> P1
- Firmagon (degarelix) / Astellas, Ferring
Trial primary completion date: Feasibility and Toxicity of Degarelix for Prostate Downsizing Prior to Permanent Seed Prostate Brachytherapy (clinicaltrials.gov) - Jan 30, 2015
P2, N=50, Recruiting, Sponsor: British Columbia Cancer Agency
Phase classification: P1b --> P1 Trial primary completion date: Oct 2013 --> Dec 2015
- || Firmagon (degarelix) / Astellas, Ferring
Trial primary completion date, Metastases: A Safety Study in Patients With Advanced Prostate Cancer Treated With FIRMAGON (clinicaltrials.gov) - Jan 29, 2015
P=N/A, N=1500, Active, not recruiting, Sponsor: Ferring Pharmaceuticals
Trial primary completion date: Oct 2013 --> Dec 2015 Trial primary completion date: Nov 2017 --> May 2018
- Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion, HEOR: RA-PROACTIVE: Long Term Effects of an Early Response to Certolizumab Pegol (CZP, Cimzia (clinicaltrials.gov) - Jan 28, 2015
P=N/A, N=152, Completed, Sponsor: UCB Pharma
Trial primary completion date: Nov 2017 --> May 2018 Active, not recruiting --> Completed
- Xtandi (enzalutamide) / Pfizer, Astellas, Firmagon (degarelix) / Astellas, Ferring
Enrollment change, Trial withdrawal, Trial primary completion date, IO biomarker: A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy (clinicaltrials.gov) - Jan 26, 2015
P2, N=0, Withdrawn, Sponsor: Kenneth Pienta, MD
Active, not recruiting --> Completed N=27 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Sep 2018 --> Jan 2015
- |||||||||| Cimzia (certolizumab pegol) / Astellas, UCB
New P3 trial: CIMPACT: Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO) (clinicaltrials.gov) - Jan 26, 2015
P3, N=540, Not yet recruiting, Sponsor: UCB Biopharma S.P.R.L.
- ||||| Firmagon (degarelix) / Astellas, Ferring
New P1/2 trial, Monotherapy: High-Dose Brachytherapy in Treating Patients With Prostate Cancer (clinicaltrials.gov) - Jan 26, 2015
P1/2, N=163, Not yet recruiting, Sponsor: Stanford University
- Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion: FasT: Observation of Treatment With Certolizumab Pegol in Daily Practice (clinicaltrials.gov) - Jan 15, 2015
P=N/A, N=1117, Completed, Sponsor: UCB Pharma
N=27 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Sep 2018 --> Jan 2015 Active, not recruiting --> Completed
- | Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion: A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease (clinicaltrials.gov) - Jan 12, 2015
P3, N=402, Completed, Sponsor: UCB Pharma
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Enrollment open: Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer (clinicaltrials.gov) - Jan 8, 2015
P2, N=100, Recruiting, Sponsor: Millennium Pharmaceuticals, Inc.
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||||| Menopur (menotropin) / Ferring
New P4 trial: HRT Versus MOS for Endometrial Preparation Prior to FET in Non PCOS Patients (clinicaltrials.gov) - Jan 5, 2015
P4, N=150, Not yet recruiting, Sponsor: Mansoura University
- |||| Rekovelle (follitropin delta) / Ferring
Enrollment open: A Dose-response Trial Using FE 999049 in Japanese Women Undergoing in Vitro Fertilisation (IVF) / Intracytoplasmic Sperm Injection (ICSI) Treatment (clinicaltrials.gov) - Jan 4, 2015
P2, N=144, Recruiting, Sponsor: Ferring Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| Cimzia (certolizumab pegol) / Astellas, UCB
New P3 trial: CIMPASI-2: A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO) (clinicaltrials.gov) - Dec 29, 2014
P3, N=225, Recruiting, Sponsor: UCB Biopharma S.P.R.L.